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Background: Cardiovascular disease is the primary cause of death in chronic kidney disease (CKD). Left ventricular hypertrophy (LVH) mediates 
this relationship and its prevalence drastically rises throughout the course of CKD. Patients with CKD develop marked elevations in circulating 
levels of the phosphorus-regulating hormone, fibroblast growth factor (FGF) 23, and these levels increase progressively as the renal capacity for 
phosphorus excretion declines. While compensatory elevations in FGF23 maintain normal serum phosphate levels, recent prospective clinical studies 
demonstrated a dose-dependent association between elevated FGF23 levels and greater risks of major cardiovascular events and mortality. FGF23 
was independently associated with greater left ventricular mass and greater prevalence of LVH. However, these small cross-sectional studies were 
unable to determine whether FGF23 directly contributes to LVH or is simply a biomarker of toxicity of other factors.
Methods: In the present study, we investigate the role of FGF23 in the pathogenesis of LVH in human and experimental models.
Results: Using a large, nationally-representative, racially diverse cohort of CKD patients, we confirm that FGF23 levels and rates of LVH are elevated 
in CKD, and that elevated FGF23 is independently associated with LVH. We demonstrate that FGF23 directly induces pathological hypertrophy of 
isolated cardiac myocytes, and that mice develop LVH following intra-ventricular or intravenous injection of FGF23. We report that klotho-deficient 
mice, an established animal model for constitutively elevated FGF23 levels, develop LVH, and klotho heterozygotes manifest FGF23 levels and an 
LVH phenotype that are intermediate between wild-type and klotho-deficient mice. Finally, we demonstrate that administering an FGF receptor 
blocker to the 5/6 nephrectomy rat model of CKD attenuates the severity of LVH without reducing the animals’ markedly elevated blood pressure.
Conclusion: These results establish a direct causal role for elevated FGF23 in the pathogenesis of LVH and suggest a novel mechanism to explain 
the high rates of LVH in patients with CKD.
